

Presented at the 2023 Alzheimer Association International Conference in Amsterdam, the Netherlands, on 17 July.

JAD

Journal of Alzheimer's Disease

2023 Editorial Board Update

Editor-in-Chief
George Perry

Initial Goal of JAD

1. Create an open forum to promote novelty
2. Create a worldwide community
3. Become the major forum for publication in Alzheimer's disease
4. Fast turn-over and no delays

From 2020 to spring 2023 JAD published all COVID related content open access



Future Goals of JAD

1. Continue to build onto the community through outreach to increase gender and regional diversity and other forms of equity
2. Lead the reformation of AD research to productive, novel areas
3. Develop useful tools and instruments to aid advancement
4. Making research open and accessible to all readers

JAD: Analytics

- Impact factor: **4.0** (Clarivate, JCR™, 2023)
- 5 year impact factor: 4,9 (Clarivate, JCR™, 2023)
- CiteScore: 6.4 (Scopus)
- h-index: 149 (Web of Science) – Highest of any AD journal
- h-index: 163 (SCImago Journal Rank indicator)
- h5-index: 88 (Google Scholar)
- h5-median: 138 (Google Scholar)
- JAD articles have been cited 232,763 times
- 10,454 articles published
- Average citations per item: 24.73

Policies

- Policy on the Use of Animals
- Policy on the Use of Human Subjects
- Policy on Ethics
- Policy on Data
- Policy on Investigation of Potentially Fraudulent Papers
- Financial Disclosures
- Compliance with Major Funding Agencies (including PubMed Central, NIH Public Access and RCUK)
 - Green Open Access Publishing in JAD (Self-Archiving)
 - Gold Open Access Publishing in JAD (Open Access Option EUR1800 / \$1800)

Editorial Board Policy:

- Terms of new Associate Editors will begin January 1st of the following calendar year.
- Terms can be extended by one year by performing Acts of Service with a limit of two extensions in any give year. Once this limit has been reached, additional acts of service will be applied to the goal of Senior editorship for that year.
- To elevate to Senior Editor status, an Associate Editor must complete five (5) Acts of Service during a one-year period. Guest editing a Special Issue automatically qualifies the Assoc Editor for Senior editorship in the next year.
- Senior Editors are responsible for soliciting and handling review articles and, to maintain status as Senior Editor, must solicit at least two review articles per year as part of their five (5) Acts of Service.
- 75% of corresponding authors accept the Associate Editor invitation.



Editorial Board

Editor-in-Chief

George Perry

Managing Editor

Beth Kumar

Deputy Editors

Jesus Avila
Daniela Galimberti
Paula Moreira
Xiongwei Zhu

Reviews Editor

Madeleine Hackney

Ethics Editor

Allyson Rosen

Senior Editors

Carlo Abbate
Saima Hilal
Jianping Jia
Nagaendran Kandiah
Pravat Mandal
Sid O'Bryant
Cyrus Raji
Jagannatha Rao KS
Russell Swerdlow
Liyong Wu
Jin-Tai Yu
Ling-Qiang Zhu

Prevention Editor

Dharma Singh Khalsa


Scientometrics Editor

Aaron A. Sorensen

Regional Editors

Gabrielle Britton
Kimberly Campbell
Gloria Patricia Cardona-Gomez
Sergio Ferreira
Illana Gozes
Jianping Jia
Amos Korczyn
Ricardo Maccioni
Pravat Mandal
Colin Masters
Akihiko Nunomura
Ruth Peters
Juan Zhou

Location of Editorial Board





Top Reviewers in 2023

Fabricio Oliveira, Jianping Jia, Jan Willem van Dalen, J. Wesson Ashford, Jerzy Beltowski, Jordi Matias-Guiu, Yan-Jiang Wang

Editors with the Most Acts-of-Service in 2023

Jin-Tai Yu (22), Ling-Qiang Zhu (12), Jianping Jia (6)

Analytics of JAD Board and Authors



JAD Supports the Diversity & Inclusion Statement

Taking Action*

The journal supports the IOS Press Diversity and Inclusion Statement and we are making changes relating to SDG 5 (gender equality) and SDG 10 (reduced inequalities) in terms of diversity.

Two recent appointments to the JAD Editorial Board means we now have an equal number of female and male representation within the **senior team** (i.e., looking at only the positions of Deputy Editor and Editor-in-Chief):

- **Deputy Editor: Daniela Galimberti, PhD**
- **Reviews Editor: Madeleine Hackney, PhD**

*Further actions will be taken in due course



We also appointed (female) **regional editors**, with an aim to increase journal submissions from these regions:

- **Kimberly Ashby-Mitchell** (*Caribbean*)
- **Gloria Patricia Cardona-Gómez** (*South America*)
- **Illana Gozes** (*Middle East*)
- **Ruth Peters** (*Oceania*)
- **Juan (Helen) Zhou** (*Asia*)

Outreach to Africa

JAD provides an open forum for original research to expedite our understanding of Alzheimer's disease. As such, JAD is committed to encouraging researchers from all parts of the world to participate in the journal and its publication. Currently, we have been expanding our outreach to researchers in Africa, including the following countries:

- Algeria
- Benin
- Egypt
- Ghana
- Kenya
- Morocco
- Mozambique
- Namibia
- Nigeria
- Senegal
- South Africa
- Tanzania
- Tunisia
- Uganda




Published/Accepted Articles:

- Grobler C, van Tongeren M, Gettemans J, Kell DB, Pretorius E. Alzheimer's Disease: A Systems View Provides a Unifying Explanation of Its Development. J Alzheimers Dis. 2023;91(1):43-70. **South Africa**
- Akuffo KO, Wooten BR, Ofori-Asare W, Osei Duah Junior I, Kumah DB, Awuni M, Obiri-Yeboah SR, Horthman SE, Addo EK, Acquah EA, Boateng BS, Johnson EJ. Macular Pigment, Cognition, and Visual Function in Younger Healthy Adults in Ghana. J Alzheimers Dis. 2023;94(3): doi: 10.3233/JAD-230233. **Ghana**

Citations to JAD (Per Year)


Times Cited and Publications Over Time



Top 10 journals citing JAD:

- FRONTIERS IN AGING NEUROSCIENCE
- INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- FRONTIERS IN NEUROLOGY
- BRAIN SCIENCES
- FRONTIERS IN NEUROSCIENCE
- ALZHEIMERS & DEMENTIA
- AGEING RESEARCH REVIEWS
- NUTRIENTS
- BIOMOLECULES
- CELLS

Articles Received and Accepted




	2016	2017	2018	2019	2020	2021	2023
Received	1291	1179	1300	1350	1610	1446	1284
Accepted	715	698	672	710	815	869	778
Accept Rate	55%	59%	52%	53%	51%	59%	61%

2020: COVID lockdown submission explosion


2023: Post-COVID lockdown paper dip

Optional Open Access



	2016	2017	2018	2019	2020	2021	2023
Total Articles	715	698	672	710	815	869	835
Open Access	91	122	114	121	154	216	178
Percentage	13%	17%	17%	17%	19%	25%	21%

Turnaround Time (submission to first decision)



	2016	2017	2018	2019	2020	2021	2023
Average (days)	27.6	28.1	28.8	26.9	25.4	29.0	32.0

Average turnaround time (5-year period, 2018-2023): 28.4 days

Publishing Schedule 2023

new issue every 2 weeks

Volume 91:

Number 1, 2023
Number 2, 2023
Number 3, 2023
Number 4, 2023

Volume 92:

Number 1, 2023
Number 2, 2023
Number 3, 2023
Number 4, 2023

Volume 93:

Number 1, 2023
Number 2, 2023
Number 3, 2023
Number 4, 2023

Volume 94:

Number 1, 2023
Number 2, 2023
Number 3, 2023
Number 4, 2023
Supplement 1, 2023 "New Molecular Pathways",
Edited by Jagannatha Rao et al.

Volume 95:

Number 1, 2023
Number 2, 2023
Number 3, 2023
Number 4, 2023

Volume 96:


Number 1, 2023
Number 2, 2023
Number 3, 2023
Number 4, 2023

Published Special Issues/Mini-Forums:

- **Mini-Forum:** Communicating and Using Dementia Risk Evidence (Guest Editor: Allyson Rosen)
- **Supplement:** Novel Molecular Pathways and Therapeutic Challenges in Neurodegenerative Diseases (Guest Editors: Jagannatha Rao KS and others)

Upcoming:

- **Supplement:** Omics Approaches in Alzheimer's Disease Research (Guest Editor: Sudeshna Das)
- **Supplement:** Pro-oxidants and Antioxidants in Alzheimer's Disease (Guest Editor: Pravat Mandal)
- **Mini-Forum:** Neuropsychological Impact and Mechanisms of Creative Movement: Implications for Rehabilitation for Aging, Neurodegenerative Disease, and Neurotrauma (Guest Editor: Madeleine E. Hackney)



Book Series: Advances in Alzheimer's Disease (AIAD)

- Vol. 1 *Handbook of Animal Models in Alzheimer's Disease*, G. Casadesus (Ed.), 2011
- Vol. 2 *Handbook of Imaging The Alzheimer Brain*, J.W. Ashford, A. Rosen, M. Adamson, P. Bayley, O. Sabri, A. Furst, S.E. Black, M. Weiner (Eds.), 2011
- Vol. 3 *Alzheimer's Disease: Advances for a New Century*, G. Perry, X. Zhu, M.A. Smith[†], A. Sorensen, J. Avila (Eds.), 2013
- Vol. 4 *Handbook of Depression in Alzheimer's Disease*, G.S. Smith (Ed.), 2015
- Vol. 5 *Handbook of Infectious Origin of Alzheimer's Disease*, J. Miklossy (Ed.), 2017
- Vol. 6 *Alzheimer's Disease: New Beginnings*, G. Perry, J. Avila, P.I. Moreira, A. Sorensen, M. Tabaton (Eds.), 2018
- Vol. 7 *Handbook of Traumatic Brain Injury and Neurodegenerative Disease*, R.J. Castellani (Ed.), 2020
- Vol. 8 *Handbook of Air Pollution and Alzheimer's Disease*, L. Calderón-Garcidueñas (Ed.), 2021
- Vol. 9 *Handbook of Microbiome and Gut-Brain-Axis in Alzheimer's Disease*, G. Pasinetti (Ed.), 2022
- **Vol. 10 *Handbook of Prevention in Alzheimer's Disease*, C. Raji, Y. Leng, JW. Ashford, D. Singh Khalsa (Eds), 2024 **IN PROGRESS****
- **Vol. 11 *Handbook of Intervention in Alzheimer's Disease*, C. Raji, Y. Leng, JW. Ashford, D. Singh Khalsa (Eds), 2024 **IN PROGRESS****
- **Vol. 12 *Therapeutic Trials in Alzheimer's Disease: Where Are We Now?*, P. Moreira, J. Avila, D. Galimberti, A. Sorensen, X. Zhu, G. Plascencia-Villa, G. Perry (Eds), 2024 **IN PROGRESS****

Ethics Section: Blog on Biomarker Communication MiniForum

Editor: Allyson Rosen, PhD, ABPP-CN

Home

Protecting Progress: Communicating and Using Dementia Risk Evidence

by Allyson Rosen, PhD, ABPP-CN on 29 November 2022



A transformation in our understanding of dementia is happening through advances in biomarkers, genetics, and other data used as dementia risk evidence (DRE) promising a future for precision dementia care. These data are increasingly informing clinical diagnosis and management; however, advances are also revealing ethical and legal gaps and practical questions about how to use and communicate these data. Investigators often use DRE in research. When participants ask for their personal results, investigators have concerns. Will data that was intended to study groups be valid for individuals? Will sharing data cause distress? Debates around sharing DRE became heated when blood-based amyloid tests and amyloid reducing drugs appeared poised to enable clinicians easily to identify people with elevated brain amyloid and reduce it with a drug. Such an approach would transform the traditional role of genetic and biomarker-based DRE from investigational to foundational; however, then the high costs, uncertain clinical benefits and risks of the therapy led to an urgent need for education to support clinical decision making. Further complicating DRE use are direct to consumer genetic testing and increasingly available biomarker testing. Withholding DRE becomes less feasible and public education around responsible use and understanding become vital. A critical answer to these legal and ethical issues is supporting education that clearly delineates known risks, benefits, and gaps in knowledge, and provides communication to promote understanding among researchers, clinicians, patients, and all stakeholders. The purpose of this mini forum is to explain issues relevant to dementia. Contributors include relevant submissions to our Ethics Review and from the Advisory Group on Risk Evidence Education for Dementia (AGREEDementia.org).

Give us your opinion by commenting below!

Would you want your dementia-related biomarkers/genetics?

Would you want your results in your medical record?

Should researchers share all data with participants if they are asked?

What questions have we missed?

For more discussion, join AGREEDementia.org!

Papers in the Mini-Forum

The introduction to the Mini-Forum [1] provides an overview and describes general concepts and resource documents that support more informed discussions for individuals and interdisciplinary groups. The first contribution is a proposed "Bill of Rights", from

Popular Blog Posts

[MOST VIEWED](#) | [COMMENTS](#)

[Dr. Oskar Fischer's Mysterious Little Alzheimer's Germ](#)

[Alzheimer's Disease and Spirochetosis: A Causal Relationship](#)

[Time to Dismount](#)

[What is wrong with Alzheimer's disease clinical research?](#)

[Alzheimer's Disease, the Sweet Trail to Neuroprotection](#)

[Is There Alzheimer's Disease?](#)

[What is A \$\beta\$?](#)

["Checkmate the Onset of Dementia": Prescribing Chess to Elderly People as a Primary Prevention of Dementia](#)

[The Prion Hypothesis at Forty: Enlightening or Deceptive?](#)

[Extracellular Tau Spreading](#)

Ethics Section: Continuing Education with AGREEDementia.org

Editor: Allyson Rosen, PhD, ABPP-CN



Bringing Together the People Who Use Dementia Risk Evidence

Scientific advances increasingly bring us closer to knowing whether our brains are developing illnesses that lead to dementia long before we are aware. This information can be used by researchers to study how to prevent dementia and allows us to take action to prepare. But risk information cannot perfectly predict this future and it is upsetting. Our group helps guide when and how to tell people this risk information so that people understand it and get the information they want. We have working groups of diverse members including people living with dementia, scientists, clinicians, ethicists, lawyers and many others who address the complex issues surrounding risk communication for dementia. We welcome new members who want to become involved.

Continuing Education



Ethics Section: Recent Articles & Topics

Editor: Allyson Rosen, PhD, ABPP-CN

Dementia Risk Evidence: Ethical Use

- Introduction to the Mini-Forum provides a tutorial (Rosen, 2022)
- Producing Continuing Education videos at www.agreedementia.org/ CE button
 - Incorporating Biomarkers in Diagnosis (Rosen, Schindler)-ILEAD
 - Ethical Use of Biomarkers and Genetics (Largent, Roberts)-ILEAD
 - Neuropsychiatry and Biomarkers (Oliviera-organizer of multiple)-Alz.Assoc., ISTAART
 - Understanding FDA Approval of AD Biomarkers (Radoja)-ILEAD coming soon
 - Biomarkers Readiness for Use (Mielke)-ILEAD coming soon
 - A Tutorial on Approved Amyloid Reducing Drugs/Lecanumab (Ljubenkov)-ILEAD coming soon

Caregivers Delivering Cognitive Screening

- Screening for Cognitive Impairment with the Quick Memory Check: Validation of a Caregiver Administered Cognitive Screen, O'Caoimh et al. (2022)
- The Ethics of Using Caregivers as Cognitive Testers, Possin & Rosen (2022)

Inclusivity and Diversity in Biomarker Use

- Let's Not Repeat History's Mistakes: Two cautions to scientists on the use of race in Alzheimer's disease and Alzheimer's disease related dementias (AD/ADRD) research, Stites (2023)

Ethics Section:

Collaborations!

Editor: Allyson Rosen, PhD, ABPP-CN

Advisory Group on Risk Evidence Education (AGREEDementia.org)

Monthly webinars and subgroups to collaborate
www.agreedementia.org/lectures

Global CEOi/Davos Alzheimer's Collaborative

Developing clinical best practice guidance

NIA Staff and Websites for Publicity

Alzheimer's & Dementia Outreach, Recruitment & Engagement Resources (ADORE)


VA-MIRECC/ADNI/ILEAD

We can help produce webinars if clinically relevant

Alzheimer's Association (ISTAART)

Neuropsychiatric Syndromes and Biomarkers(Oliveira)
Technology and Dementia (Robillard),
Partnering with Research Participants (Walter)

All-Time Top 10 Cited Articles (Wall of Fame)

1. **Impaired insulin and insulin-like growth factor expression and signaling mechanisms in AD - is this type 3 diabetes?** de la Monte SM et al. (2005), Times Cited: **1267**
2. **Alzheimer's disease and the amyloid-beta peptide** Murphy MP and Levine H III (2010), Times Cited: **953**
3. **Oxidative Stress, Synaptic Dysfunction, and Alzheimer's Disease** Tonnie E and Trushina E (2017), Times Cited: **809**
4. **Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways** Cogswell JP et al. (2008), Times Cited: **714**
(medal winner 2009)

5. **Insulin and insulin-like growth factor expression and function deteriorate with progression of AD: Link to brain reductions in acetylcholine** de la Monte SM et al. (2005), Times Cited: **543**
6. **Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F-18]-T807** Chien DT et al. (2013) Times Cited: **512**
7. **The Amyloid-beta Oligomer Hypothesis: Beginning of the Third Decade** Cline EN (2018) Times Cited: **445 NEW IN TOP 10**
8. **Religious Orders Study and Rush Memory and Aging Project** Bennett DA et al. (2018) Times Cited: **435 NEW IN TOP 10**
9. **The Gut Microbiota and Alzheimer's Disease** Jiang CM et al. (2017), Times Cited: **424 NEW IN TOP 10**
10. **Alzheimer's Disease Results from the Cerebral Accumulation and Cytotoxicity of Amyloid beta-protein** Selkoe DJ (2001) Times Cited: **418**

Top 10 Cited Articles (Published in 2020-2021)

These are the articles that define the 2023 impact factor

1. **Neurobiology of COVID-19** Fotuhi, M et al (2020) Times Cited: **221**
2. **The Prevalence of Dementia: A Systematic Review and Meta-Analysis**, Cao, Q et al. (2020) Times Cited: **121**
3. **Short-Chain Fatty Acids and Lipopolysaccharide as Mediators Between Gut Dysbiosis and Amyloid Pathology in Alzheimer's Disease**, Marizzoni, M et al (2020) Times Cited: **115**
4. **The Effects of Confinement on Neuropsychiatric Symptoms in Alzheimer's Disease During the COVID-19 Crisis** Boutoleau-Brettonniere, C et al. (2020) Times Cited: **89**
5. **Heavy Metals Exposure and Alzheimer's Disease and Related Dementias**, Bakulski, KM et al. (2020) Times Cited: **72**
6. **Potential Novel Role of COVID-19 in Alzheimer's Disease and Preventative Mitigation Strategies**, Naughton, SX et al. (2020) Times Cited: **71**
7. **Probiotic Bifidobacterium breve in Improving Cognitive Functions of Older Adults with Suspected Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Trial** Xiao JZ et al. (2020) Times Cited: **60**
8. **Clinical and Bacterial Markers of Periodontitis and Their Association with Incident All-Cause and Alzheimer's Disease Dementia in a Large National Survey**, Beydoun, MA et al. (2020) Times Cited: **56**
9. **Alzheimer's Disease: The Link Between Amyloid-beta and Neurovascular Dysfunction**, Solis, E et al. (2020) Times Cited: **54**
10. **COVID-19: Review of a 21st Century Pandemic from Etiology to Neuro-psychiatric Implications**, Yamamoto, V et al. (2020) Times Cited: **52**

Top 10 Viewed Articles in 2022 (Popular in the Media)#

1. **Precision Medicine Approach to Alzheimer's Disease: Successful Pilot Project** Toups K et al. (2022) [Research Article] **NEW IN TOP 10**
2. **Association of COVID-19 with New-Onset Alzheimer's Disease** Wang L et al.(2022) [Short Communication] **NEW IN TOP 10**
3. **Risk of Alzheimer's Disease Following Influenza Vaccination: A Claims-Based Cohort Study Using Propensity Score Matching** Bukhbinder, AS et al. (2022) [Research article] **NEW IN TOP 10**
4. **Is Caffeine a Cognitive Enhancer?** Nehlig A (2010) [Review]
5. **Treatment Combinations for Alzheimer's Disease: Current and Future Pharmacotherapy Options** Cummings JL et al. (20191) [Review Article]
6. **Alzheimer's Disease: Key Insights from Two Decades of Clinical Trial Failures** Kim CK et al. (2022) [Research Article] **NEW IN TOP 10**
7. **Caffeine, Mental Health, and Psychiatric Disorders** Lara DR (2010) [Review Article] **NEW IN TOP 10**
8. **Caffeine and Adenosine** Ribeiro JA, Sebastião AM (2010) [Review Article] **NEW IN TOP 10**
9. **Cognitive Effects of Aerobic Exercise in Alzheimer's Disease: A Pilot Randomized Controlled Trial** Yu F et al. (2021) [Research Article]
10. **Moderate-to-High Intensity Physical Exercise in Patients with Alzheimer's Disease: A Randomized Controlled Trial** Hoffmann K et al. (2016) [Research Article]

#via IOS Press Content Website

content.iospress.com/journal-of-alzheimers-disease



Journal of Alzheimer's Disease Reports

Journal of Alzheimer's Disease Reports (JADR) publishes original research that will expedite our fundamental understanding of AD. It is an online-only journal and fully open access, launched in 2017.

JADR is abstracted/indexed in:

DOAJ, Embase, Google Scholar, Pubmed Central, Scopus, Web of Science: ESCI


2023 IMPACT FACTOR: 3.2*

Top Cited Articles:

1. Increased All-Cause Mortality by Antipsychotic Drugs: Updated Review and Meta-Analysis in Dementia and General Mental Health Care *Ralph SJ, Espinet AJ* (2018) **Times Cited: 103**
2. Aluminum Should Now Be Considered a Primary Etiological Factor in Alzheimer's Disease *Exley C* (2017) **Times Cited: 59**
3. Phosphodiesterase Inhibitors for Alzheimer's Disease: A Systematic Review of Clinical Trials and Epidemiology with a Mechanistic Rationale *Sanders O, Rajagopal L* (2017) **Times Cited: 56**

Data from Dimensions (2023)

*From Web of Science: ESCI (2023)



Year	Views
2022	47,330
2021	41,057
2020	26,150
2019	20,272
2018	16,359

Year	Articles
2022	72
2021	78
2020	49
2019	23
2018	24

Media Coverage



New Superfood? Mushrooms May Prevent Cognitive Impairment, Reduce Dementia Risk After COVID-19 Infection

FEATURED NATURAL MEDICINE

Anna Lee
Dr. Ho-Nam
April 2023



New study links multiple viral infections to a higher risk of dementia



The Youngest Person Ever Diagnosed With Alzheimer's Is Just 19 Years Old

By Osman Shabir | April 7th, 2023

A 19-year-old is the youngest person to be diagnosed with Alzheimer's disease. Neurology researcher Osman Shabir at the University of Sheffield dives into the case.




The Viruses-
Alzheimer's Link
Was Dismissed for
Years – That's
Changing

Alzheimer's disease: Is amyloid beta 42 the answer?

By Invited Researcher | October 17, 2022 | 1 comment | Print



Authors: **Andrea Sturchio**, MD, PhD Student, Clinical Neuroscience, Karolinska Institutet; **Kariem Ezat**, Research Scientist, Laboratory Medicine, Karolinska Institutet, and **Samir El Andaloussi**, Professor, Laboratory Medicine, Karolinska Institutet



Top 5 JAD Article Press Releases 2022

Association of COVID-19 with New-Onset Alzheimer's Disease (Sep 2022) – *Short Communication* in JAD 89:2) [ALTMETRIC SCORE: 2672]

Risk of Alzheimer's Disease Following Influenza Vaccination: A Claims-Based Cohort Study Using Propensity Score Matching (Aug 2022) – *Research Article* in JAD 88:3, OA [ALTMETRIC SCORE: 1440]

Potential Involvement of Varicella Zoster Virus in Alzheimer's Disease via Reactivation of Quiescent Herpes Simplex Virus Type 1 (Aug 2022) – *Research Article* in JAD 88:3 [ALTMETRIC SCORE: 992]

High Soluble Amyloid- β 42 Predicts Normal Cognition in Amyloid-Positive Individuals with Alzheimer's Disease-Causing Mutations (Oct 2022) - *Research Article* in JAD 90:1, OA [ALTMETRIC SCORE: 951]

A Decade of Decline in Serious Cognitive Problems Among Older Americans: A Population-Based Study of 5.4 Million Respondents. (Jan 2022) *Research Article* in JAD 85:1) [ALTMETRIC SCORE: 699]

Example of Successful JAD Press Release

Press Release: Risk Factor for Developing Alzheimer's Disease Increases by 50–80% in Older Adults who Caught COVID-19

Article: "Association of COVID-19 with New-Onset Alzheimer's Disease" Wang et al. (JAD, Vol. 89, Issue 2, 2022)

Risk Factor for Developing Alzheimer's Disease Increases by 50–80% in Older Adults who Caught COVID-19

15 September 2022




Cleveland, OH, USA – Older people who were infected with COVID-19 show a substantially higher risk – as much as 50% to 80% higher than a control group – of developing Alzheimer's disease within a year, according to a study of more than 6 million patients 65 and older. In a study published in the *Journal of Alzheimer's Disease*, researchers report that people 65 and older who contracted COVID-19 were more prone to developing Alzheimer's disease in the year following their COVID diagnosis. And the highest risk was observed in women at least 85 years old.

The findings showed that the risk for developing Alzheimer's disease in older people nearly doubled (0.35% to 0.68%) over a one-year period following infection with COVID. The researchers say it is unclear whether COVID-19 triggers new development of Alzheimer's disease or accelerates its emergence.

The **Altmetric Attention Score** for a research output provides an indicator of the amount of attention that it has received. The score is derived from an automated algorithm and represents a weighted count of the amount of attention we've picked up for a research output.

Data from Dimensions



Mentioned by

- 256 news outlets
- 13 blogs
- 1082 tweeters
- 6 Facebook pages
- 1 Wikipedia page
- 6 Redditors
- 1 video uploader

Website: J-Alz.com

Visitors mainly search the submission information, but there is also news, blogs, letters to the editor, and more to find!

There was a notable growth in the number of people engaging with the content compared to the previous year

Year	2022	2021	2020
Views	336,063	379,997	352,524
Visitors	138,860	126,246	119,793



The screenshot shows the homepage of the Journal of Alzheimer's Disease (JAD) website. The header includes the JAD logo, navigation links (HOME, ABOUT, NEWS, SUBMIT, CONTENTS, BLOG, MEMBERS, RANKINGS/AWARDS, JOURNAL OF ALZHEIMER'S DISEASE REPORTS), and social media sharing options. The main content area features a large image of a human head with a glowing brain, a search bar, and a "Welcome, Guest" message. Below the main image, there are sections for "News" and "Latest JAD Articles".

News:

- New UCL-led research shows people who live to be 90+ with superior thinking skills are resilient to Alzheimer's pathology in their brains
- Traumatic brain injury raises risk of brain atrophy
- Case Study Reveals Potentially Lethal Side Effects of Lecanemab for Treatment of Alzheimer's Disease

Latest JAD Articles:

- Best Medicine for Dementia: The Life-Long Defense of the Brain
- Advancing Diagnostic Certainty in Alzheimer's Disease: A Synthesis of the Diagnostic Process
- The Multifactorial Etiopathogenesis of Alzheimer's Disease: Neuroinflammation as the Major Contributor
- Concomitant Neuronal Tau Deposition and FKBP52 Decrease Is an Early Feature of Different Human and Experimental Tauopathies
- Memory, Sleep, and Tau Function

CURRENT ISSUE: Volume 93, Issue 4

Features **J-Alz.com**

Blog:

- Invite experts to write blog content on relevant, topical issues or urgent questions
- Community interaction
- A popular blog in 2020 by Elena Portacolone focused on the use of digital applications during the COVID-19 pandemic

Editor's Choice:

- A recommendation of new high-profile articles as selected by the Editor-in-Chief

Popular Content:

- See what your community is most interested in reading today

Ranking/ Awards:

- Alzheimer Award section featuring all winners since its launch in 2000
- The JAD community's selection of the 50 "game-changing" articles (2006–2015)
- The "Top 100 Investigators in AD" (up to 2009)

Letters to the Editor:

- Community interaction, encouraging discussion between site users of topics raised in Letters to the Editor

Meta-Objectives:

- Draw readers to the JAD platform
- Bring key AD research developments together
- Make it a destination for discussion across the AD community

**Coming in 2024:
Relaunch website**

JAD Facebook

 @journalad

The aim is to spread awareness of AD news and highlight JAD content. Sharing articles via social media can generate significant reach.

JAD Twitter

 @journal_ad

Followers: 1,707



Followers: 4,486

Likes: 4,203



JAD Newsletter

The best way to keep up to speed about JAD news is to sign up for the **newsletter**.

Mailings

- Newsletters are dispatched every month
- Our audience is increasing, with good engagement levels

Please feel free forward to your colleagues and share the news of our journal

Call for Papers

The *Journal of Alzheimer's Disease* welcomes submissions for its upcoming issues.

Omics Approaches in Alzheimer's Disease Research

We are pleased to invite you to participate in our Supplementary Issue on "Omics approaches in Alzheimer's Disease research" which is being prepared for the *Journal of Alzheimer's Disease*. This Supplementary Issue will focus on the application of omics strategies to characterize molecular mechanism as well as identify biomarkers and therapeutics for Alzheimer's disease (AD).

(Guest Editor: Sudeshna Das, PhD) – Deadline: July 31, 2023

Download the Call for Papers and submission instructions via: j-alz.com

Volume 93, Issue 2 / 2023 Online

SHORT COMMUNICATIONS

Serum Cathepsin S Levels Do Not Show Alterations in Different Clinical, Neuropathological, or Genetic Subtypes of Frontotemporal Dementia Patients nor in Comparison to Healthy Control Individuals

Heikkinen, Sami | Huber, Nadine | Katisko, Kasper | Kokkola, Tarja | Hartikainen, Päivi | Krüger, Johanna | Leinonen, Ville | Korhonen, Ville E. | Herukka, Sanna-Kaisa | Remes, Anne M. | Borroni, Barbara | Alberici, Antonella | Libri, Ilenia | Solje, Eino | Haapasalo, Annakaisa

A Novel c.800G>C Variant of the *ITM2B* Gene in Familial Korean Dementia

Rhyu, Jee-Min | Park, Joonhong | Shin, Byoung-Soo | Kim, Young-Eun | Kim, Eun-Joo | Kim, Ko Woon | Cho, Yong Gon



Indexed in:
PubMed/MEDLINE Web of Science Scopus

2023 ALZHEIMER AWARD

RECIPIENTS:

Henning Tiemeier, MD
Rosanne Freak-Poli, PhD

for the article

**“Loneliness, Not Social Support, Is Associated with Cognitive Decline
and Dementia Across Two Longitudinal Population-Based Cohorts”**

Journal of Alzheimer's Disease, 85(1), 295-308, 2023



Sponsored by:





Thank you for your attention!

Any questions?

Contact: editorial@j-alz.com



Sign up for news: tiny.cc/JADsignup

IMPRESSIONS FROM THE 2023 BOARD MEETING

